Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells

John M. Abraham, Fumiaki Sato, Yulan Cheng, Bogdan Paun, Takatsugu Kan, Alexandru Olaru, Zhe Jin, Jian Yang, Rachana Agarwal, Stefan David, James P. Hamilton, Tetsuo Ito, Yuriko Mori, Stephen J. Meltzer

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background. The rapidly growing field of targeted tumor therapy often utilizes an antibody, sometimes tagged with a tumor-ablating material such as radioisotope, directed against a specific molecule. Methodology/Principal findings. This report describes the discovery of nine novel decapeptides which can be radioactively labeled, bind to, and deliver 32p to colon cancer cells. The decapeptides vary from one another by one to three amino acids and demonstrate vastly different binding abilities. The most avidly binding decapeptide can permanently deliver very high levels of radioisotope to the adenocarcinoma cancer cell lines at an efficiency 35 to 150 times greater than to a variety of other cell types, including cell lines derived from other types of cancer or from normal tissue. Conclusions/Significance. This experimental approach represents a new example of a strategy, termed peptide binding therapy, for the potential treatment of colorectal and other adenocarcinomas.

Original languageEnglish (US)
Article numbere964
JournalPloS one
Issue number10
StatePublished - Oct 3 2007
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells'. Together they form a unique fingerprint.

Cite this